WILEX develops diagnostic and therapeutic products for the treatment of renal cell carcinoma.
Business Model:
Revenue: $4.1M
Employees: 51-200
Address: Grillparzerstr. 10
City: Munich
State: bavaria
Zip: 81675
Country: DE
WILEX develops diagnostic and therapeutic products for the treatment of renal cell carcinoma.
Contact Phone:
Contact Email:
Listed Exchange:
NYSE
IPO Date:
11/24/2006
Ticker Symbol:
WL6
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 5/2005 | Series C | 3 | $38.4M |
Apax Partners Earlybird Venture Capital TVM Capital Apax Partners Earlybird Venture Capital TVM Capital |
11/2006 | IPO | $70.7M |
|
3/2010 | Post-IPO Debt | 1 | $27.1M |
Yorkville Advisors Yorkville Advisors |
3/1999 | Venture Round | 1 | - |
Earlybird Venture Capital Earlybird Venture Capital |
3/1999 | Venture Round | 1 | - |
Earlybird Venture Capital Earlybird Venture Capital |
---|
Announced Date | Name | Price |
---|---|---|
11/2010 | Heidelberg Pharma |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|